drug · intermediate · partly written
Lantidra (donislecel)
Lantidra is purified islet cells from deceased donors, infused into the portal vein of adults with type 1 diabetes and repeated severe hypoglycemia; it works only while immune-suppressing drugs are taken.
Also called: donislecel, donislecel-jujn, allogeneic pancreatic islet cellular therapy
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
What it is
Donor islets: the insulin-making clusters from a deceased donor's pancreas, purified and dripped through a catheter into the liver's portal vein. The FDA approved it on 28 June 2023 for a narrow group of adults with type 1 diabetes. It works only while drugs hold the immune system back. 12
Reported, not yet replicated
How the cells are placed and kept more
Each lot is made from a deceased donor pancreas and infused by catheter into the hepatic portal vein; nothing is cut out of the patient. The islets are small enough to lodge in the liver's small vessels, which is the physical reason they stay. They are kept alive by immunosuppressive drugs. In the Edmonton work a large mass of islets mattered too: a mean of 11,547 islet equivalents per kilogram of body weight, from two donor pancreases for every patient. 13
Reported, not yet replicated
What the FDA saw deep
Two non-randomised single-arm studies enrolled 30 participants with type 1 diabetes and hypoglycemic unawareness. The FDA says the large treatment effect is attributed to the product, but found the primary composite endpoint not interpretable because of substantial missing data and because participants had met or nearly met it at baseline; 83 percent had no severe hypoglycemia in the year before. Adverse events are those of the product, of the portal-vein procedure and of the immunosuppression required to keep the islets alive.
History that explains the ceiling: registry data before 2000 showed only 8 percent of islet recipients insulin-free at one year; a glucocorticoid-free regimen (sirolimus, tacrolimus, daclizumab) brought seven of seven patients to insulin independence (median follow-up 11.9 months); at 5 years in 65 patients about 10 percent kept insulin independence, with a median duration of 15 months. 134
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Fda product
LANTIDRA (donislecel-jujn)
Manufacturer
CellTrans Inc.
Mechanism
Islets of Langerhans purified from a deceased donor's pancreas are infused through a catheter into the hepatic portal vein. The islets lodge in small vessels of the liver and secrete insulin. The FDA states that concomitant immunosuppression is required for beta-cell survival, and that discontinuing it results in loss of islet cells and of endogenous insulin production. 1
Established
Delivery route
Must survive
A microembolizing infusion into the portal vein: the FDA reports a median peak rise in portal pressure of 3 mmHg (range -3 to 18), risk of portal hypertension and portal vein branch thrombosis, and in two subjects pressures of 22 mmHg or more that required stopping the procedure. Then the recipient's immune system, held back by immunosuppressive drugs. 1
Reported, not yet replicated
Assays used
Insulin independence (freedom from exogenous insulin)
The FDA relied on this because it considered the sponsor's primary composite endpoint not interpretable (substantial missing data, and participants at baseline had met or nearly met it). 1
Reported, not yet replicated
Side effects
Serious adverse reactions overall
90 percent of subjects had at least one serious adverse reaction. Serious infections occurred in 83 percent; 211 infections were reported in 26 subjects; 16 malignancy events in 11 subjects over 0.3 to 13.2 years of follow-up, three life-threatening; anemia in 24 (80 percent). 1
Reported, not yet replicated
Procedure events
Among 56 portal infusions: one life-threatening liver laceration, one intra-abdominal hemorrhage, two perihepatic hematomata with prolonged hospitalization; three subjects needed transfusions for procedural events. 1
Reported, not yet replicated
Deaths
Two subjects died during the study period: one from sepsis (multi-organ failure) and one from progressive microischemic disease. 1
Reported, not yet replicated
Verdict
Outcome
mixed
Why
It works in the narrow sense: of 30 participants in two single-arm studies (one to three infusions each), 21 (70 percent) were free of exogenous insulin for more than a year, 10 (33 percent) for at least 5 years (maximum 12.8 years), and 5 never achieved any insulin independence. The FDA notes that restoration of insulin independence does not occur spontaneously in type 1 diabetes. The price is the immunosuppression: eight subjects had to stop it because of severe infections, which loses the islets. Earlier Edmonton data show the same limit: after 5 years in 65 patients, about 80 percent still had C-peptide but only about 10 percent kept insulin independence. So the ceiling is graft loss under drugs as much as rejection. Approval is for a narrow group, with the benefit judged against these risks. 14
Reported, not yet replicated
Failure mode
Teach this
In one sentence
Donor islets can free some people with type 1 diabetes from insulin, but only as long as they accept immune suppression and its risks. 1
Reported, not yet replicated
The five-minute version
Purified donor islets are infused into the portal vein and lodge in the liver. 21 of 30 trial participants had over a year free of insulin; 90 percent had a serious adverse reaction, many tied to immunosuppression. The FDA said the studies primary endpoint could not be interpreted. Hence a narrow label. 1
Reported, not yet replicated
What a listener will ask
Why not use my own cells?
In this disease the beta cells are lost, and this product is made from a donor pancreas, so drugs are needed to stop rejection.
The common wrong idea
Once the cells are infused, they are permanent.
Islet graft function fades and depends on continuing immunosuppression; the long-term Edmonton follow-up shows it.
The one citation to hand over: 1
Still open here
- Insulin-independence durability beyond the 30 people studied is not in the sources read.
- How does it compare with stem-cell-derived islets (zimislecel) over longer follow-up? Only a 14-participant interim report abstract was read.
Not yet written: Off targets.
Linked from
Sources
- U.S. Food and Drug Administration. Summary Basis for Regulatory Action: LANTIDRA (donislecel-jujn). FDA (2023). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- U.S. Food and Drug Administration. LANTIDRA (donislecel-jujn): product page. FDA (2023). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., et al.. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine (2000). paper; opened 2026-11-17 all records citing this
- Ryan, E. A., Paty, B. W., Senior, P. A., et al.. Five-year follow-up after clinical islet transplantation. Diabetes (2005). paper; opened 2026-11-17 all records citing this
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2023
- Regulatory status
- approved
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/drugs/lantidra.json